Certara provides integrated solutions consisting of computer-based models supported by scientific consulting services that span the discovery, preclinical and clinical stages of drug development. Certara’s solutions aim to provide clients with reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions.
Stephen McLean, a partner at Arsenal and co-head of the firm’s Healthcare Group, said, “We are delighted to invest in this exciting company which is making such an important contribution to improving the productivity of the drug development process. The average cost today of researching and developing a new drug is more than $1.5 billion and takes 10-15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare and Certara will make a difference.”
Jim Hopkins, Certara’s chief executive officer, commented, “Arsenal shares our vision for applying analytics and scientific informatics to facilitate the distribution of pharmaceutical knowledge. After careful assessment, we were impressed with Arsenal’s deep understanding of our mission and our value. We are confident that this is the right match for Certara and one that will benefit both our customers and staff.”